Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers

被引:6
|
作者
Abdalla, Thaer S. A. [1 ]
Klinkhammer-Schalke, Monika [2 ]
Zeissig, Sylke Ruth [2 ,3 ]
Tol, Kees Kleihues-van [2 ]
Honselmann, Kim C. [1 ]
Braun, Ruediger [1 ]
Bolm, Louisa [1 ]
Lapshyn, Hryhoriy [1 ]
Litkevych, Stanislav [1 ]
Zemskov, Sergii [4 ]
Begum, Nehara [1 ,5 ]
Kulemann, Birte [1 ]
Hummel, Richard [1 ]
Wellner, Ulrich Friedrich [1 ]
Keck, Tobias [1 ]
Deichmann, Steffen [1 ]
机构
[1] Univ Med Ctr Schleswig Holstein, Dept Surg, Ratzeburger Allee 160,Campus Lubeck, D-23564 Lubeck, Germany
[2] Network Care Qual & Res Oncol ADT, German Canc Registry Grp Soc German Tumor Ctr, Berlin, Germany
[3] Univ Wurzburg, Inst Clin Epidemiol & Biometry ICE B, Wurzburg, Germany
[4] Bogomolets Natl Med Univ, Dept Gen Surg, UA-01601 Kiev, Ukraine
[5] Johannes Wesling Klinikum Minden, Dept Surg, Minden, Germany
关键词
Pancreatic neuroendocrine neoplasms; Resection margin; Prognostic factors; Population-based analysis; GUIDELINES; DIAGNOSIS; SURVIVAL;
D O I
10.1007/s00432-023-04785-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe available literature regarding outcome after pancreatic resection in locally advanced non-functional pNEN (LA-pNEN) is sparse. Therefore, this study evaluates the current survival outcomes and prognostic factors in after resection of LA-pNEN.Materials and methodsThis population-based analysis was derived from 17 German cancer registries from 2000 to 2019. Patients with upfront resected non-functional non-metastatic LA-pNEN were included.ResultsOut of 2776 patients with pNEN, 277 met the inclusion criteria. 137 (45%) of the patients were female. The median age was 63 +/- 18 years. Lymph node metastasis was present in 45%. G1, G2 and G3 pNEN were found in 39%, 47% and 14% of the patients, respectively. Resection of LA-pNEN resulted in favorable 3-, 5- and 10-year overall survival of 79%, 74%, and 47%. Positive resection margin was the only potentially modifiable independent prognostic factor for overall survival (HR 1.93, 95% CI 1.71-3.69, p value = 0.046), whereas tumor grade G3 (HR 5.26, 95% CI 2.09-13.25, p value < 0.001) and lymphangiosis (HR 2.35, 95% CI 1.20-4.59, p value = 0.012) were the only independent prognostic factors for disease-free survival.ConclusionResection of LA-pNEN is feasible and associated with favorable overall survival. G1 LA-pNEN with negative resection margins and absence of lymph node metastasis and lymphangiosis might be considered as cured, while those not fulfilling these criteria might be considered as a high-risk group for disease progression. Herein, negative resection margins represent the only potentially modifiable prognostic factor in LA-pNEN but seem to be influenced by tumor grade.
引用
收藏
页码:8535 / 8543
页数:9
相关论文
共 44 条
  • [31] Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
    Weiss, L.
    Heinemann, V.
    Fischer, L.
    Gieseler, F.
    Hoehler, T.
    Mayerle, J.
    Quietzsch, D.
    Reinacher-Schick, A.
    Schenk, M.
    Seipelt, G.
    Siveke, J.
    Stahl, M.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Dorman, K.
    Zhang, D.
    Westphalen, B.
    Haas, M.
    Boeck, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S164 - S164
  • [32] Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer An Analysis of Patients from German Centers in the TRUST Study
    Schneider, Claus-Peter
    Heigener, David
    Schott-von-Roemer, Kathrin
    Guetz, Sylvia
    Laack, Eckart
    Digel, Werner
    Guschall, Wolf-Ruediger
    Franke, Andreas
    Bodenstein, Heinrich
    Schmidtgen, Claudia
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (12) : 1446 - 1453
  • [33] Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
    C. Ostheimer
    M. Mäurer
    N. Ebert
    D. Schmitt
    D. Krug
    R. Baumann
    C. Henkenberens
    F. A. Giordano
    L. Sautter
    Guerra López
    D. F. Fleischmann
    M. Niyazi
    L. Käsmann
    D. Kaul
    A. H. Thieme
    C. Billiet
    S. Dobiasch
    C. R. Arnold
    M. Oertel
    J. Haussmann
    T. Gauer
    Y. Goy
    C. Suess
    S. Ziegler
    C. M. Panje
    C. Baues
    M. Trommer
    T. Skripcak
    D. Medenwald
    Strahlentherapie und Onkologie, 2021, 197 : 385 - 395
  • [34] Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
    Faehling, Martin
    Schumann, Christian
    Christopoulos, Petros
    Hoffknecht, Petra
    Alt, Juergen
    Horn, Marlitt
    Eisenmann, Stephan
    Schlenska-Lange, Anke
    Schuett, Philipp
    Steger, Felix
    Brueckl, Wolfgang M.
    Christoph, Daniel C.
    LUNG CANCER, 2020, 150 : 114 - 122
  • [35] Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
    C. Ostheimer
    M. Mäurer
    N. Ebert
    D. Schmitt
    D. Krug
    R. Baumann
    C. Henkenberens
    F. A. Giordano
    L. Sautter
    Guerra López
    D. F. Fleischmann
    M. Niyazi
    L. Käsmann
    D. Kaul
    A. H. Thieme
    C. Billiet
    S. Dobiasch
    C. R. Arnold
    M. Oertel
    J. Haussmann
    T. Gauer
    Y. Goy
    C. Suess
    S. Ziegler
    C. M. Panje
    C. Baues
    M. Trommer
    T. Skripcak
    D. Medenwald
    Strahlentherapie und Onkologie, 2021, 197 : 560 - 561
  • [36] Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group
    Ostheimer, C.
    Maeurer, M.
    Ebert, N.
    Schmitt, D.
    Krug, D.
    Baumann, R.
    Henkenberens, C.
    Giordano, F. A.
    Sautter, L.
    Lopez, Guerra
    Fleischmann, D. F.
    Niyazi, M.
    Kasmann, L.
    Kaul, D.
    Thieme, A. H.
    Billiet, C.
    Dobiasch, S.
    Arnold, C. R.
    Oertel, M.
    Haussmann, J.
    Gauer, T.
    Goy, Y.
    Suess, C.
    Ziegler, S.
    Panje, C. M.
    Baues, C.
    Trommer-Nestler, M.
    Skripcak, T.
    Medenwald, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (05) : 385 - 395
  • [37] Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy
    Rose, Peter G.
    Java, James
    Whitney, Charles W.
    Stehman, Frederick B.
    Lanciano, Rachelle
    Thomas, Gillian M.
    DiSilvestro, Paul A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2136 - U160
  • [38] Comprehensive analysis of predictive factors for efficacy in concurrent chemoradiotherapy for locally advanced non-small cell lung cancer, utilizing individual patient data from the Japan lung cancer society integrated clinical trial database: Is there room for further improvement?
    Ozawa, Yuichi
    Yamamoto, Kouji
    Sugawara, Shunichi
    Niho, Seiji
    Ohe, Yuichiro
    Okamoto, Hiroaki
    Hotta, Katsuyuki
    Ikeda, Norihiko
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
    Lohaus, Fabian
    Linge, Annett
    Tinhofer, Inge
    Budach, Volker
    Gkika, Eleni
    Stuschke, Martin
    Balermpas, Panagiotis
    Roedel, Claus
    Avlar, Melanie
    Grosu, Anca-Ligia
    Abdollahi, Amir
    Debus, Juergen
    Bayer, Christine
    Belka, Claus
    Pigorsch, Steffi
    Combs, Stephanie E.
    Moennich, David
    Zips, Daniel
    von Neubeck, Claere
    Baretton, Gustavo. B.
    Loeck, Steffen
    Thames, Howard D.
    Krause, Mechthild
    Baumann, Michael
    RADIOTHERAPY AND ONCOLOGY, 2014, 113 (03) : 317 - 323
  • [40] Next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck (LASCCHN) for assessment of mutational patterns and their interference with outcome after adjuvant chemoradiation: Results from a multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
    Tinhofer, I
    Budach, V
    Linge, A.
    Lohaus, F.
    Gkika, E.
    Stuschke, M.
    Balermpas, P.
    Roedel, C.
    Avlar, M.
    Grosu, A. L.
    Abdollahi, A.
    Debus, J.
    Belka, C.
    Pigorsch, S.
    Combs, S. E.
    Moennich, D.
    Zips, D.
    Weichert, W.
    Krause, M.
    Baumann, M.
    Oncology Research and Treatment, 2015, 38 : 176 - 176